Frederick Carl Koerner, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 9 | 2009 | 482 | 1.300 |
Why?
|
| Carcinoma, Ductal, Breast | 10 | 2009 | 1100 | 0.900 |
Why?
|
| Breast Neoplasms | 47 | 2015 | 20672 | 0.780 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 12 | 2009 | 947 | 0.770 |
Why?
|
| Carcinoma in Situ | 7 | 2001 | 799 | 0.730 |
Why?
|
| Breast | 14 | 2014 | 1950 | 0.590 |
Why?
|
| Nipples | 5 | 2009 | 214 | 0.580 |
Why?
|
| Papilloma | 2 | 2010 | 148 | 0.560 |
Why?
|
| Carcinoma, Papillary | 5 | 2010 | 779 | 0.510 |
Why?
|
| Breast Diseases | 3 | 2004 | 442 | 0.410 |
Why?
|
| Hyperplasia | 5 | 2006 | 1181 | 0.380 |
Why?
|
| Carcinoma | 9 | 1998 | 2360 | 0.320 |
Why?
|
| Precancerous Conditions | 4 | 2006 | 966 | 0.270 |
Why?
|
| Fibrocystic Breast Disease | 2 | 2001 | 102 | 0.250 |
Why?
|
| Retinal Artery Occlusion | 1 | 2005 | 75 | 0.240 |
Why?
|
| Vitrectomy | 3 | 2005 | 358 | 0.240 |
Why?
|
| Fibroadenoma | 2 | 2014 | 43 | 0.240 |
Why?
|
| Receptors, Progesterone | 7 | 2001 | 1094 | 0.240 |
Why?
|
| Sialoglycoproteins | 2 | 2001 | 318 | 0.230 |
Why?
|
| Pathology, Surgical | 1 | 2004 | 151 | 0.220 |
Why?
|
| X-Ray Microtomography | 2 | 2015 | 426 | 0.210 |
Why?
|
| Receptors, Steroid | 1 | 2001 | 155 | 0.190 |
Why?
|
| Blindness | 1 | 2005 | 612 | 0.190 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2005 | 499 | 0.180 |
Why?
|
| Cystic Duct | 1 | 1999 | 19 | 0.180 |
Why?
|
| Mammary Glands, Human | 2 | 2014 | 200 | 0.170 |
Why?
|
| Cadherins | 2 | 2001 | 901 | 0.170 |
Why?
|
| Neuroendocrine Tumors | 2 | 1996 | 591 | 0.170 |
Why?
|
| Epithelium | 1 | 2004 | 1684 | 0.170 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2008 | 46 | 0.160 |
Why?
|
| Receptors, Estrogen | 8 | 2001 | 2183 | 0.150 |
Why?
|
| Cyclin D1 | 3 | 1998 | 462 | 0.150 |
Why?
|
| Macula Lutea | 1 | 1999 | 151 | 0.150 |
Why?
|
| Immunohistochemistry | 15 | 2006 | 11348 | 0.150 |
Why?
|
| Vitreous Body | 1 | 1999 | 389 | 0.150 |
Why?
|
| Ovary | 1 | 2001 | 982 | 0.140 |
Why?
|
| Calcinosis | 3 | 2001 | 1492 | 0.140 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 1996 | 29 | 0.140 |
Why?
|
| Diagnosis, Differential | 9 | 2014 | 12945 | 0.130 |
Why?
|
| Neoplasm Proteins | 4 | 1998 | 3693 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2005 | 2155 | 0.130 |
Why?
|
| Phyllodes Tumor | 1 | 2014 | 53 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 1996 | 455 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 1999 | 564 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 1994 | 299 | 0.110 |
Why?
|
| Microwaves | 1 | 1994 | 188 | 0.110 |
Why?
|
| Retinal Diseases | 1 | 1999 | 687 | 0.110 |
Why?
|
| Female | 58 | 2015 | 378808 | 0.110 |
Why?
|
| Immunity, Mucosal | 1 | 1996 | 491 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 2015 | 954 | 0.100 |
Why?
|
| Mastectomy | 3 | 2009 | 1782 | 0.100 |
Why?
|
| History, 19th Century | 2 | 2004 | 721 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 4 | 1998 | 2843 | 0.100 |
Why?
|
| Collagen | 2 | 1998 | 2669 | 0.100 |
Why?
|
| Stromal Cells | 2 | 2010 | 1350 | 0.090 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2005 | 108 | 0.090 |
Why?
|
| Keratins | 3 | 2006 | 515 | 0.090 |
Why?
|
| Middle Aged | 36 | 2015 | 212833 | 0.090 |
Why?
|
| Microscopy, Electron | 5 | 1998 | 2665 | 0.090 |
Why?
|
| Osteopontin | 2 | 2001 | 295 | 0.080 |
Why?
|
| Mammography | 6 | 2015 | 2466 | 0.080 |
Why?
|
| Humans | 64 | 2015 | 739219 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3599 | 0.080 |
Why?
|
| Aged | 30 | 2015 | 162667 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6176 | 0.070 |
Why?
|
| Aged, 80 and over | 14 | 2015 | 57639 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 3432 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 1938 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 954 | 0.070 |
Why?
|
| Chromogranins | 2 | 1997 | 162 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2004 | 2741 | 0.070 |
Why?
|
| Vitreous Detachment | 1 | 2005 | 22 | 0.070 |
Why?
|
| Pseudophakia | 1 | 2005 | 62 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2005 | 978 | 0.070 |
Why?
|
| Aphakia, Postcataract | 1 | 2005 | 54 | 0.070 |
Why?
|
| Visual Acuity | 3 | 2005 | 2517 | 0.060 |
Why?
|
| Adult | 30 | 2015 | 213375 | 0.060 |
Why?
|
| Scleral Buckling | 1 | 2005 | 84 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2005 | 231 | 0.060 |
Why?
|
| Cicatrix | 1 | 2010 | 751 | 0.060 |
Why?
|
| Cyclins | 2 | 1997 | 601 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2001 | 3670 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2013 | 3452 | 0.060 |
Why?
|
| Cytoplasm | 2 | 1999 | 1536 | 0.060 |
Why?
|
| Staining and Labeling | 2 | 2001 | 1110 | 0.050 |
Why?
|
| Proteins | 3 | 1992 | 6074 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13622 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 490 | 0.050 |
Why?
|
| Oncogene Proteins | 2 | 1997 | 749 | 0.050 |
Why?
|
| Eyelid Neoplasms | 2 | 2005 | 90 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 1995 | 1800 | 0.050 |
Why?
|
| Mucins | 2 | 1997 | 563 | 0.050 |
Why?
|
| Foam Cells | 1 | 2001 | 71 | 0.050 |
Why?
|
| Retinal Detachment | 1 | 2005 | 408 | 0.050 |
Why?
|
| Genes, RAG-1 | 1 | 2001 | 68 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 699 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 1999 | 2967 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 4025 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 760 | 0.040 |
Why?
|
| Epiretinal Membrane | 1 | 1999 | 69 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2005 | 1058 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1998 | 322 | 0.040 |
Why?
|
| Retrospective Studies | 11 | 2014 | 76632 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2001 | 575 | 0.040 |
Why?
|
| Species Specificity | 1 | 2001 | 2481 | 0.040 |
Why?
|
| Hemosiderin | 1 | 1996 | 43 | 0.040 |
Why?
|
| Silver Staining | 1 | 1996 | 65 | 0.040 |
Why?
|
| Synaptophysin | 1 | 1996 | 141 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 1998 | 641 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1997 | 723 | 0.030 |
Why?
|
| Smooth Muscle Tumor | 1 | 1996 | 67 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 14721 | 0.030 |
Why?
|
| DNA, Protozoan | 1 | 1996 | 237 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 1996 | 255 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2149 | 0.030 |
Why?
|
| Toxoplasma | 1 | 1996 | 150 | 0.030 |
Why?
|
| Antibodies, Protozoan | 1 | 1996 | 251 | 0.030 |
Why?
|
| Microtomy | 1 | 1994 | 47 | 0.030 |
Why?
|
| Adipocytes | 1 | 2001 | 1171 | 0.030 |
Why?
|
| Organelles | 1 | 1996 | 269 | 0.030 |
Why?
|
| Acute Disease | 1 | 2005 | 7127 | 0.030 |
Why?
|
| Melanocytes | 1 | 1997 | 515 | 0.030 |
Why?
|
| Vulvar Neoplasms | 1 | 1996 | 269 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1676 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3382 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1998 | 1083 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 545 | 0.030 |
Why?
|
| Syndrome | 1 | 1999 | 3241 | 0.030 |
Why?
|
| Lymphatic Metastasis | 4 | 2013 | 2897 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2013 | 62691 | 0.030 |
Why?
|
| Granular Cell Tumor | 1 | 1992 | 52 | 0.030 |
Why?
|
| Fluoxymesterone | 1 | 1991 | 12 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1994 | 981 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2001 | 2410 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1991 | 135 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 1998 | 9124 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 40385 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2001 | 4138 | 0.020 |
Why?
|
| Silver | 1 | 1991 | 120 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 2937 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2013 | 2215 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1991 | 347 | 0.020 |
Why?
|
| Progesterone | 1 | 1994 | 772 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1994 | 4549 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1992 | 610 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1045 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1413 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 321 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1183 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 970 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 2587 | 0.020 |
Why?
|
| Adolescent | 5 | 2014 | 85409 | 0.020 |
Why?
|
| Calcium | 1 | 2001 | 5739 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1994 | 1356 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2008 | 154 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2013 | 8272 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 624 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2005 | 21691 | 0.020 |
Why?
|
| Mucin-1 | 1 | 1991 | 542 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1994 | 1548 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2001 | 13006 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1701 | 0.020 |
Why?
|
| Cheek | 1 | 2005 | 62 | 0.020 |
Why?
|
| Animals | 4 | 2001 | 168358 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 4521 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 23292 | 0.010 |
Why?
|
| Pregnancy | 3 | 2001 | 29003 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2008 | 692 | 0.010 |
Why?
|
| Male | 8 | 2005 | 348967 | 0.010 |
Why?
|
| Child | 3 | 2001 | 77029 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2008 | 793 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 1991 | 4832 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 11411 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6870 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 2687 | 0.010 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 38941 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 13237 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2005 | 15191 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1990 | 1318 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 3768 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2001 | 257 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1995 | 1755 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1995 | 8395 | 0.010 |
Why?
|
| Karyotyping | 1 | 2001 | 1241 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6451 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1994 | 15035 | 0.010 |
Why?
|
| Prognosis | 3 | 1994 | 28901 | 0.010 |
Why?
|
| Genes, ras | 1 | 2001 | 690 | 0.010 |
Why?
|
| Young Adult | 2 | 2014 | 56252 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2001 | 547 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 4211 | 0.010 |
Why?
|
| Metaplasia | 1 | 1997 | 313 | 0.010 |
Why?
|
| Neoplasm Staging | 4 | 1992 | 10961 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2008 | 53036 | 0.010 |
Why?
|
| Risk Factors | 3 | 2014 | 71972 | 0.010 |
Why?
|
| Time Factors | 1 | 1998 | 40040 | 0.010 |
Why?
|
| Telomerase | 1 | 2001 | 729 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1637 | 0.010 |
Why?
|
| Melanoma | 1 | 1994 | 5446 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 1583 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 2634 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1986 | 3453 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 3524 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1997 | 2049 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 4575 | 0.010 |
Why?
|
| S Phase | 1 | 1994 | 422 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2001 | 2381 | 0.010 |
Why?
|
| Receptor, erbB-2 | 2 | 1994 | 2370 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1996 | 469 | 0.010 |
Why?
|
| Myoglobin | 1 | 1992 | 160 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1997 | 1117 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1992 | 259 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1996 | 726 | 0.010 |
Why?
|
| Biopsy | 2 | 1995 | 6722 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 9598 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1997 | 1524 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1994 | 1609 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1989 | 829 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 6310 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 15152 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 2238 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1995 | 5180 | 0.000 |
Why?
|
| Survival Rate | 2 | 1992 | 12760 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1990 | 642 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14555 | 0.000 |
Why?
|
| Base Sequence | 1 | 1997 | 12807 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 13815 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 2 | 1994 | 9259 | 0.000 |
Why?
|
| Abdomen | 1 | 1990 | 1102 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 18124 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 7716 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1989 | 1477 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1994 | 10248 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1997 | 11471 | 0.000 |
Why?
|
| Lymphoma | 1 | 1987 | 1871 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 8605 | 0.000 |
Why?
|
| Massachusetts | 1 | 1990 | 8668 | 0.000 |
Why?
|
| Radiography | 1 | 1987 | 6997 | 0.000 |
Why?
|
| Age Factors | 1 | 1992 | 18347 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 80995 | 0.000 |
Why?
|